microRNAs associated to anthracycline-induced cardiotoxicity in women with breast cancer: A systematic review and pathway analysis

Pereira, Jéssica Diniz; Tosatti, Jéssica Abdo Gonçalves; Simões, Ricardo; Luizon, Marcelo R.; Gomes, Karina Braga; Alves, Michelle Teodoro

doi:10.1016/j.biopha.2020.110709

Cited by 28 publications

(22 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Upregulation of let-7a can predict the occurrence of cardiotoxicity ( 102 ). The downregulation of the expression of let-7f, a family member of let-7, signified the appearance of cardiac dysfunction because of its good correlation with N-terminal pro-B type natriuretic peptide (NT-proBNP) ( 98 , 103 ). In addition to the let-7 family, miR-1 is another important biomarker, and has also been used as a clinical indicator.…”

Section: Mirnas and Membrane Transportmentioning

confidence: 99%

The Role of miRNAs in the Resistance of Anthracyclines in Breast Cancer: A Systematic Review

Zhong

Lao

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Breast cancer has been reported as the most common cancer in women globally, with 2.26 million new cases in 2020. While anthracyclines are the first-line drug for breast cancer, they cause a variety of adverse reactions and drug resistance, especially for triple-negative breast cancer, which can lead to poor prognosis, high relapse, and mortality rate. MicroRNAs (miRNAs) have been shown to be important in the initiation, development and metastasis of malignancies and their abnormal transcription levels may influence the efficacy of anthracyclines by participating in the pathologic mechanisms of breast cancer. Therefore, it is essential to understand the exact role of miRNAs in the treatment of breast cancer with anthracyclines. In this review, we outline the mechanisms and signaling pathways involved in miRNAs in the treatment of breast cancer using anthracyclines. The role of miRNA in the diagnosis, prognosis and treatment of breast cancer patients is discussed, along with the involvement of miRNAs in chemotherapy for breast cancer.

show abstract

Section: Mirnas and Membrane Transportmentioning

confidence: 99%

The Role of miRNAs in the Resistance of Anthracyclines in Breast Cancer: A Systematic Review

Zhong

Lao

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…miRNAs in serum can be easily obtained and detected using miRNA sequencing methods ( 10 , 75 , 76 ). Therefore, miRNAs have been investigated as non-invasive biomarkers for the early diagnosis of DIC ( 77 ). Table 2 summarizes the clinical significance of miRNAs and their potential roles in DIC.…”

Section: Mirnas For the Diagnosis And Prognosis Of Doxorubicin-induced Cardiomyopathymentioning

confidence: 99%

MicroRNAs as Biomarkers and Therapeutic Targets in Doxorubicin-Induced Cardiomyopathy: A Review

Chen

2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Doxorubicin is a broad-spectrum chemotherapy drug applied in antitumor therapy. However, its clinical utility is limited by its fatal cardiotoxicity. Doxorubicin (DOX)-induced cardiomyopathy (DIC) begins with the first DOX dose and is characterized by being cumulative dose-dependent, and its early diagnosis using common detection methods is very difficult. Therefore, it is urgent to determine the underlying mechanism of DIC to construct treatment strategies for the early intervention before irreversible damage to the myocardium occurs. Growing evidence suggests that microRNAs (miRNAs) play regulatory roles in the cardiovascular system. miRNAs may be involved in DIC by acting through multiple pathways to induce cardiomyocyte injury. Recent studies have shown that the dysregulation of miRNA expression can aggravate the pathological process of DIC, including the induction of oxidative stress, apoptosis, ion channel dysfunction and microvascular dysfunction. Current findings on the roles of miRNAs in DIC have led to a wide range of studies exploring candidate miRNAs to be utilized as diagnostic biomarkers and potential therapeutic targets for DIC. In this review, we discuss frontier studies on the roles of miRNAs in DIC to better understand their functions, develop relevant applications in DIC, discuss possible reasons for the limitations of their use and speculate on innovative treatment strategies.

show abstract

“…Most myomiRs are expressed both in heart and skeletal muscle: miR-1, miR-133a, miR-133b, miR-486, and miR-499 [56], while some are only expressed in one muscle tissue: cardiospecific miR-208a and skeletal muscle-specific miR-206 [57]. Evidence illustrates that the dysregulation of myomiRs, along with metabolism-related miRNAs, was correlated to adverse cardiac remodelling and toxicity in both preclinical and clinical studies (for review, see Pellegrini et al [22], Pereira et al [58], and Riggeri et al [59]). In neonatal cardiac rat models, the doxorubicin-induced upregulation of miR-146a facilitated cell death in myocytes by targeting ErbB4 and therefore caused cardiotoxicity [60].…”

Section: Cardiorespiratory Toxicitymentioning

confidence: 99%

“…A systematic review for breast cancer patients suggested that let-7, miR-20a, and miR-210 may serve as biomarkers for anthracycline-based cardiotoxicity during chemotherapy [58]. In the rat model treated with doxorubicin at increasing doses, the level of cTnT was significantly elevated in the 18mg/kg dose.…”

Section: Othersmentioning

confidence: 99%

MicroRNAs as Potential Biomarkers for Exercise-Based Cancer Rehabilitation in Cancer Survivors

Jiang

Ghias

Gupta

et al. 2021

Life

View full text Add to dashboard Cite

Expression and functions of microRNAs (miRNAs) have been widely investigated in cancer treatment-induced complications and as a response to physical activity, respectively, but few studies focus on the application of miRNAs as biomarkers in exercise-based cancer rehabilitation. Research has shown that certain miRNA expression is altered substantially due to tissue damage caused by cancer treatment and chronic inflammation. MiRNAs are released from the damaged tissue and can be easily detected in blood plasma. Levels of the miRNA present in peripheral circulation can therefore be used to measure the extent of tissue damage. Moreover, damage to tissues such as cardiac and skeletal muscle significantly affects the individual’s health-related fitness, which can be determined using physiologic functional assessments. These physiologic parameters are a measure of tissue health and function and can therefore be correlated with the levels of circulating miRNAs. In this paper, we reviewed miRNAs whose expression is altered during cancer treatment and may correlate to physiological, physical, and psychological changes that significantly impact the quality of life of cancer survivors and their role in response to physical activity. We aim to identify potential miRNAs that can not only be used for monitoring changes that occur in health-related fitness during cancer treatment but can also be used to evaluate response to exercise-based rehabilitation and monitor individual progress through the rehabilitation programme.

show abstract

microRNAs associated to anthracycline-induced cardiotoxicity in women with breast cancer: A systematic review and pathway analysis

Cited by 28 publications

References 83 publications

The Role of miRNAs in the Resistance of Anthracyclines in Breast Cancer: A Systematic Review

The Role of miRNAs in the Resistance of Anthracyclines in Breast Cancer: A Systematic Review

MicroRNAs as Biomarkers and Therapeutic Targets in Doxorubicin-Induced Cardiomyopathy: A Review

MicroRNAs as Potential Biomarkers for Exercise-Based Cancer Rehabilitation in Cancer Survivors

Contact Info

Product

Resources

About